Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07025824

Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

Randomized Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
220 (estimated)
Sponsor
Technische Universität Dresden · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to compare the effectiveness and tolerability of two conditioning chemotherapies prior to allogeneic stem cell transplantation. The following will also be investigated: * Survival * Remission and Relapse rate * Engraftment or graft failure * Graft versus Host Disease (GvHD)

Conditions

Interventions

TypeNameDescription
DRUGTreosulfan (Treo)10 g/m2 intravenous
DRUGMelphalan (Mel)140 mg/m2 intravenous
DRUGFludarabine (Flud)30 mg/m2 intravenous

Timeline

Start date
2025-09-01
Primary completion
2028-12-01
Completion
2028-12-01
First posted
2025-06-18
Last updated
2025-09-03

Locations

4 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT07025824. Inclusion in this directory is not an endorsement.

Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogene (NCT07025824) · Clinical Trials Directory